Stakeholders Identification– Targeted list of stakeholders’ for the In-depth interview. Research Institutions/ Universities - UCC, UDS, UMat, Atomic Energy, GAEC, School of Nuclear and Allied Sciences. Ministries Departments and Agencies (MDA’s)– EPA, Ministry of Health, Ministry of Environment and Science, CSIR, Ministry of Mines and Energy, Ministry of Roads and Transport, AMA, Zoomlion, Ministry of Food and Agriculture Industries – Tullow Oil, Anglogold Ashanti, Newmont Ghana, Gold Fields, TOR, Bulk Oil Storage and Transportation, Ghana Ports and Harbours, Ghana Standards Authority. Civil Societies and NGO’s – WHO, UNICEF, UNDP, Traditional Leaders, CONIWAS, Association of Environment and Health. Contact key persons or experts in Occupational and Environmental Health field. Questionnaires should include a checklist. The meeting went ahead to include in the framework the levels of stakeholders, specifics, Contact Persons, Timelines and the Expected Output to aid in the categorization of the framework. The meeting agreed that all members should take a look at Edith’s report and provide comments, however, this questionnaires must be sent to all the stakeholders. Timelines- 26th June, 2013 Point-person: – Dr. Stephens, Julius, Hannah, with Strong Input from Edith and Prof. Quakyi to Contact Key Persons. 3.2 Priority Research for Capacity Building- Extractive Industry mainly Mining, Oil and Gas, Agriculture and Disease Control Activiites Eg. Indoor residual spraying versus burden on chronic diseases.

Abstract

Tafenoquine is a promising new 8-aminoquinoline drug that may be useful for malaria prophylaxis in non-pregnant persons with normal glucose-6-phosphate dehydrogenase (G6PD) function. A randomized, double-blind, placebo-controlled chemoprophylaxis trial was conducted with adult residents of northern Ghana to determine the minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium falciparum. The primary end point was a positive malaria blood smear result during the 13 weeks of study drug coverage. Relative to the placebo, all 4 tafenoquine dosages demonstrated significant protection against P. falciparum infection: for 25 mg/week, protective efficacy was 32% (95% confidence interval [CI], 20%-43%); for 50 mg/week, 84% (95% CI, 75%-91%); for 100 mg/week, 87% (95% CI, 78%-93%); and for 200 mg/week, 86% (95% CI, 76%-92%). The mefloquine dosage of 250 mg/week also demonstrated significant protection against P. falciparum infection (protective efficacy, 86%; 95% CI, 72%-93%). There was little difference between study groups in the adverse events reported, and there was no evidence of a relationship between tafenoquine dosage and reports of physical complaints or the occurrence of abnormal laboratory parameters. Tafenoquine dosages of 50, 100, and 200 mg/week were safe, well tolerated, and effective against P. falciparum infection in this study population.

Description

Keywords

EMTREE drug terms: mefloquine; tafenoquine EMTREE medical terms: abdominal pain; adult; aged; arthralgia; article; backache; blood smear; chemoprophylaxis; clinical trial; confidence interval; controlled clinical trial; controlled study; diarrhea; dose response; double blind procedure; drug efficacy; drug eruption; drug safety; drug tolerability; dysentery; female; gastritis; gastrointestinal symptom; Ghana; headache; human; laboratory test; major clinical study; malaria; malaria control; male; musculoskeletal disease; myalgia;

Citation

Hale, B. R., Owusu-Agyei, S., Fryauff, D. J., Koram, K. A., Adjuik, M., Oduro, A. R., . . . Hoffman, S. L. (2003). A rand 44. Hale, B. R., Owusu-Agyei, S., Fryauff, D. J., Koram, K. A., Adjuik, M., Oduro, A. R., . . . Hoffman, S. L. (2003). A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against plasmodium falciparum. Clinical Infectious Diseases, 36(5), 541-549.

Endorsement

Review

Supplemented By

Referenced By